^
Association details:
| Biomarker: | NARS2 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
Published date:
01/11/2022
Excerpt:
We identified 27 SMGs, including four novel SMGs (COL3A1, NRAS, NARS2, and DCC) that are associated with ICI efficacy and well-known driver genes....NARS2 mutations were associated with an elevated ORR (OR: 0.15, 95% CI: 0.03–0.57, p = 0.008... a shortened PFS was observed in patients with NARS2 mutations (HR: 2.52, 95% CI: 1.12–5.68, p = 0.03...
DOI:
10.3389/fimmu.2021.798474